Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03515356 · ClinicalTrials.gov registry record · NA
Exercise to Reduce Chemotherapy-Induced Peripheral Neuropathy
A NA study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 54
- Enrollment target
NCT03515356 is a NA study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 54 participants.
The verdict
NCT03515356, a NA study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
Study Summary
This randomized, controlled, pilot experiment will evaluate the effects of an aerobic walking intervention on OIPN (oxaliplatin-induced peripheral neuropathy) in patients with gastrointestinal (GI) cancer who are already prescribed oxaliplatin (85 mg/m2 every other week for at least six cycles) by their oncologists. Oxaliplatin is a standard chemotherapy treatment for invasive GI cancers that causes OIPN in 85-95% of patients.
Interventions
- BEHAVIORAL MI-Walk Intervention
- BEHAVIORAL Physical Activity Education Pamphlet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2018-06-13 |
| Est. Completion | 2019-06-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03515356
The ClinicalTrials.gov registry entry for NCT03515356 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MI-Walk Intervention is the first listed.
NCT03515356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03515356 about?
NCT03515356 is a clinical study titled "Exercise to Reduce Chemotherapy-Induced Peripheral Neuropathy". This randomized, controlled, pilot experiment will evaluate the effects of an aerobic walking intervention on OIPN (oxaliplatin-induced peripheral neuropathy) in patients with gastrointestinal (GI) cancer who are already prescribed oxaliplatin (85 mg/m2 every other week for at least six cycles) by t...
What is the current status of trial NCT03515356?
This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2018-06-13. Estimated completion is 2019-06-24.
What interventions are being tested in trial NCT03515356?
The interventions under investigation include: MI-Walk Intervention (BEHAVIORAL), Physical Activity Education Pamphlet (BEHAVIORAL).
Who is sponsoring clinical trial NCT03515356?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.